STOCK TITAN
  1. Home
  2. Sec-filings
  3. GILD
  4. [13F-HR] GILEAD SCIENCES, INC. SEC Filing

Gilead Sciences (GILD) reports $1.65B in institutional holdings on latest Form 13F

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
13F-HR

Rhea-AI Filing Summary

Gilead Sciences, Inc. filed a quarterly institutional holdings report as an institutional investment manager. The report is a Form 13F Holdings Report, indicating that all reportable holdings for this manager are included. The filing covers 5 reportable positions with an aggregate reported value of $1,648,747,919, rounded to the nearest dollar. One additional manager, Gilead Therapeutics A1 Unlimited Co, is listed as an other included manager in the filing.

Positive

  • None.

Negative

  • None.
Form 13F Information Table Entry Total 5 Number of reportable positions included in the Form 13F information table
Form 13F Information Table Value Total $1,648,747,919 Aggregate value of securities reported, rounded to the nearest dollar
Number of Other Included Managers 1 Count of additional institutional investment managers listed in the report
Form 13F regulatory
"Form 13F Summary Page --------------------- | Report Summary"
A Form 13F is a quarterly filing that large investment managers must submit to disclose their holdings in publicly traded stocks and certain other securities. It acts like a peek into the portfolios of big investors, helping other market participants see what large players are buying or selling and offering clues about investment trends, crowded trades, and potential market impact.
Institutional Investment Manager regulatory
"The institutional investment manager filing this report"
13F HOLDINGS REPORT regulatory
"Report Type (Check only one.) X | 13F HOLDINGS REPORT."

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

FAQ

What did Gilead Sciences (GILD) file in this Form 13F?
Gilead Sciences filed a Form 13F Holdings Report as an institutional investment manager, indicating that all of its reportable equity and related securities positions are included in this single report for the covered quarter.

How many positions and what total value are reported by Gilead Sciences (GILD)?
The Form 13F lists 5 reportable positions with a combined reported value of $1,648,747,919, rounded to the nearest dollar. This represents the aggregate market value of the securities included in the Form 13F information table.

Is this Gilead Sciences (GILD) Form 13F a full holdings report or a notice?
It is marked as a 13F HOLDINGS REPORT, not a notice or combination report. This means all reportable holdings of Gilead Sciences, Inc. as the reporting manager are included in this filing rather than being reported by other managers.

Which other manager is included in Gilead Sciences (GILD) Form 13F?
The filing lists Gilead Therapeutics A1 Unlimited Co as one other included manager, with Form 13F File Number 028-25083. This entity is associated with certain positions reported under Gilead’s Form 13F report.

Who signed the Gilead Sciences (GILD) Form 13F and in what capacity?
The report was signed by Andrew D. Dickinson, who is the Executive Vice President and Chief Financial Officer of Gilead Sciences, Inc. He signed on behalf of the reporting manager, certifying the information as true, correct and complete.

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F COVER PAGE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
Report for the Calendar Year or Quarter Ended: 06-30-2026
Check here if Amendment Amendment Number:
This Amendment (Check only one.): is a restatement.
adds new holdings entries.
Institutional Investment Manager Filing this Report:
Name: GILEAD SCIENCES, INC.
Address: 333 LAKESIDE DR
FOSTER CITY, CA 94404
Form 13F File Number: 028-25078
CRD Number (if applicable):
SEC File Number (if applicable):

The institutional investment manager filing this report and the person by whom it is signed hereby represent that the person signing the report is authorized to submit it, that all information contained herein is true, correct and complete, and that it is understood that all required items, statements, schedules, lists, and tables, are considered integral parts of this form.

Person Signing this Report on Behalf of Reporting Manager:
Name: Andrew D. Dickinson
Title: Executive Vice President and Chief Financial Officer
Phone: 650-574-3000
Signature, Place, and Date of Signing:
/s/ Andrew D. Dickinson FOSTER CITY, CA 08-03-2026
[Signature] [City, State] [Date]
Report Type (Check only one.):
X 13F HOLDINGS REPORT. (Check here if all holdings of this reporting manager are reported in this report.)
13F NOTICE. (Check here if no holdings reported are in this report, and all holdings are reported by other reporting manager(s).)
13F COMBINATION REPORT. (Check here if a portion of the holdings for this reporting manager are reported in this report and a portion are reported by other reporting manager(s).)
Form 13F Summary Page
Report Summary:
Number of Other Included Managers: 1
Form 13F Information Table Entry Total: 5
Form 13F Information Table Value Total: 1,648,747,919
(round to nearest dollar)
List of Other Included Managers:
Provide a numbered list of the name(s) and Form 13F file number(s) of all institutional investment managers with respect to which this report is filed, other than the manager filing this report.
[If there are no entries in this list, state "NONE" and omit the column headings and list entries.]
No. Name Form 13F File No. CRD No. (if applicable) SEC File No. (if applicable) CIK
1 Gilead Therapeutics A1 Unlimited Co 028-25083 0002055207

Source: View Original Filing on SEC EDGAR